259 related articles for article (PubMed ID: 21092001)
1. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
[TBL] [Abstract][Full Text] [Related]
3. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
[TBL] [Abstract][Full Text] [Related]
4. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
Giorgini A; Capsoni F; Podda M; Lleó A; Battezzati PM; Ongari AM; Selmi C; Benetti A; Malinverno F; Rossaro L; Gershwin ME; Zuin M
Ann N Y Acad Sci; 2009 Sep; 1173():847-57. PubMed ID: 19758237
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
Koskinas J; Zacharakis G; Sidiropoulos J; Elefsiniotis J; Savvas S; Kotsiou S; Kountouras D; Schina M; Kostopoulos P; Archimandritis A
J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Liu YL; Du XF; Chen XY; Ma LN; Guo DD; Lu JF; Cao ZH; Zhang YH
Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
Tandon P; Doucette K; Fassbender K; Vandermeer B; Durec T; Dryden DM
J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
[TBL] [Abstract][Full Text] [Related]
8. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
Tarantino L; De Rosa A; Tambaro O; Ripa C; Celiento M; Schiano A
Infez Med; 2009 Mar; 17(1):20-3. PubMed ID: 19359820
[TBL] [Abstract][Full Text] [Related]
9. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
[TBL] [Abstract][Full Text] [Related]
10. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Mac Nicholas R; Norris S
Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
[TBL] [Abstract][Full Text] [Related]
11. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
12. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Lebray P; Nalpas B; Vallet-Pichard A; Broissand C; Sobesky R; Serpaggi J; Fontaine H; Pol S
Antivir Ther; 2005; 10(6):769-76. PubMed ID: 16218177
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Roomer R; Hansen BE; Janssen HL; de Knegt RJ
Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
[TBL] [Abstract][Full Text] [Related]
14. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients.
Fukuda A; Kobayashi H; Teramura K; Yoshimoto S; Ohsawa N
Cytokines Cell Mol Ther; 2000 Sep; 6(3):149-54. PubMed ID: 11140884
[TBL] [Abstract][Full Text] [Related]
15. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
[TBL] [Abstract][Full Text] [Related]
16. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
17. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence.
Lodato F; Azzaroli F; Tamè MR; Di Girolamo M; Buonfiglioli F; Mazzella N; Cecinato P; Roda E; Mazzella G
World J Gastroenterol; 2009 Nov; 15(43):5449-54. PubMed ID: 19916175
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
[TBL] [Abstract][Full Text] [Related]
19. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
